Sheng-Hsiang Lin

Prevention of new-onset chronic kidney disease with renin–angiotensin system blockers in type 2 diabetes with preserved kidney function

Renin–angiotensin system (RAS) blockers, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are known to slow chronic kidney disease (CKD) progression in patients with established renal impairment. However, whether RAS blockade ca...